Antibodies immunogens

Ricin [9009-86-3], a phytotoxin found in the seeds of the castor oil plant Acinus communis, conjugated to murine monoclonal antibody (Immunogen Corp.), has been approved by the U.S. Food and Dmg Administration (FDA) for the treatment of patients with B-ceU leukemia and lymphoma (59). 

Pseudomonas aeruginosa membrane protein F Epitope display on cowpea mosaic virus in cowpea leaf Elicited specific antibodies. Immunogenic in mice when delivered parenterally. Mice protected when challenged with model chronic pulmonary infection with P. aeruginosa. 19, 83... 

Enterotoxigenic E. coli B subunits of the heat labile toxin (LTB) Maize seed Elicited neutralizing antibodies. Immunogenic when administered orally. Serum and secretory immune responses in humans. Partially protective in mouse gut fluid assay. 27-29, 89, unpublished data... 

Respiratory syncytial virus fusion protein Tomato fruit Mice developed serum and mucosal RSV-F- -specific antibodies. Immunogenic in mice when delivered orally. 31... 

Transmissible gastroenteritis coronavirus N-terminal domain of the spike glycoprotein (S) Arabidopsis leaf gS elicited virus-neutralizing antibodies. -Immunogenic when administered parenterally. 114... 

Enterotoxigenic E. coli epitope and rotavirus epitope fused to CTB Potato tuber Mice developed detectable levels of serum and intestinal antibodies. Immunogenic in mice against ETEC, rotavirus, and V. cholerae when delivered orally. Symptoms reduced in passively immunized mouse neonates following rotavirus challenge. 63... 

Antibody immunogenicity remains one of the inherent therapeutic limitations associated with administration of murine monoclonals to human subjects. In most instances, a single injection of the murine monoclonal will elicit an immune response in 50-80 per cent of patients. Human anti-mouse antibodies (HAMA) will generally be detected within 14 days of antibody administration. Repeated administration of the monoclonal (usually required if the monoclonal is used for therapeutic purposes) will increase the HAMA response significantly. It will also induce an HAMA response in the majority of individuals who display no such response after the initial injection. The HAMA response will effectively and immediately destroy subsequent doses of monoclonal administered. In practice, therefore, therapeutic efficacy of murine monoclonals is limited to the first and, at most, the second dose administered. 

Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mount Sinai J Med 2005 72 250-6. 

As a low molecular weight compound DAS is not significantly immunogenic, ie, it is a hapten and thus requires conjugation to a suitable antigenic carrier in order to eUcit a successfiil antibody response in animals. DAS treated with succinic anhydride results in the D AS—hemisuccinate (DAS—HMS) shown. 

As shown in Table 2, free DAS, as expected, is its own best displacing agent, whereas only DAS—HMS showed any appreciable displacing capabiUty. This can be expected because the hemisuccinate linker is also immunogenic and leads to the production of antibodies specific for the linker in the polyclonal antibody population. AH the other toxins had at least lOOx less the avidity for the antibody, illustrating the specificity of the aDAS for DAS. 

The active immunotherapeutic approach is specific and based on the premise that tumor antigens are immunogenic and the host is sufficientiy immunocompetent to mount an effective immune response to an autologous tumor. Theoretically, a weak or suppressed host immune system that had allowed the formation of a tumor may be overridden by active immunization or immunostimulation. In practice, vaccines composed of so-called autologous tumor extracts have been used to treat patients with malignant melanoma (73), and purified melanoma tumor-associated antigens have been used to ehcit antibody responses in melanoma patients (74). 

The first mouse monoclonal antibody specific for human CD3 was produced in 1979 and named orthoclone OKT3. Aside from its use in the laboratory, OKT3 became the first anti-CD3 antibody to be utilized in transplantation medicine, but its wider application was hampered by its immunogenic and mitogenic properties (reviewed in [6]). Consequently, humanized and engineered anti-CD3 antibodies were developed to circumvent these limitations (Table 1). Since T cells and the TCR are involved in many immunological diseases, it is not surprising that the application of CD3 antibodies is not restricted to the field of transplantation. For example, CD3 antibodies are tested in clinical studies of diseases such as autoimmune diabetes (type 1 diabetes), immune-mediated inflammatory arthritis and inflammatory bowel disease [7]. 

Davio et al. (43) report efforts to obtain monoclonal antibodies (mAbs) to STX. Because STX is a small molecule of approximately 300 daltons, well below the size necessary for immunogenicity, a carrier molecule must be conjugated to the hapten (STX). This technique must minimize alterations of the antigenic form. For the anti-STX antibodies tested to date, the ratios of immunoassay response factor to pharmacological potency for various STX derivatives differ substantially, the immunoassay being virtually unresponsive to some of the common natural derivatives (44). 

Utility. Insufficient data Is available on the measurement of 1,25(0H)2D3 for evaluation of Its utility In clinical medicine. A major breakthrough In methodology will be needed before routine application will be possible. This could come with the development of a battery of radioimmunoassays for the measurement of all of the vitamin D metabolites. So far, however, the development of antibodies to vitamin D and Its metabolites has been limited by apparently Irreversable changes In the Important B ring of the sterol which occur during Its conjugation to Immunogenic proteins. 

The EMSIL method may prove useful in cytochemical applications where lack of substrate immunogenicity precludes antibody generation, or for which enzymes specific to the... 

The chemical adducts formed by reaction of aldehydes with lysine residues form highly immunogenic epitopes, and antibodies have been prepared specific for malondialdehyde- and 4-hydroxynonenal-conjugated LDL (Gonen et al., 1987 Yla-Herttuala et al., 1989 Jurgens et al., 1990). These antibodies cross-react with material in atherosclerotic lesions but not normal tissue, thus supporting the central role of lipid peroxidation in the patho nesis of atherosclerosis (Yla-Herttuala et al., 1989, 1991). 

Figure 8 Structure of immunogen haptens for pyrethroids with spacer arm attachment at the a-position of the alcohol moiety. Since the whole pyrethroid molecule is available for recognition by the antibody, assays resulting from these immunogens were selective for the parent pyrethroids...

Figure 9 Structure of the immunogen hapten used to generate antibodies for a type I pyrethroid class-selective assay. Pyrethroids lacking an a-cyano group are generally termed type I. This hapten exposed the features most common to type I pyrethroids, the phenoxybenzyl group, the cyclopropyl group and the lack of a cyano group, resulting in antibodies that recognized permethrin, phenothrin, resmethrin and bioresmethrin, but not cypermethrin...

---